{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:38:16Z","timestamp":1791340696311,"version":"4.3.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1016\/j.amjmed.2003.09.034","type":"journal-article","created":{"date-parts":[[2004,2,12]],"date-time":"2004-02-12T05:15:06Z","timestamp":1076562906000},"page":"263-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":296,"title":["The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease"],"prefix":"10.1016","volume":"116","author":[{"given":"Ursula C","family":"Brewster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2003.09.034_BIB1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0002-9343(76)90888-3","article-title":"The biochemistry of the renin-angiotensin system and its role in hypertension","volume":"60","author":"Skeggs","year":"1976","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.HYP.16.4.363","article-title":"Angiotensin I converting enzyme and the changes in our concepts through the years","volume":"16","author":"Erdos","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB3","series-title":"Bailliere's Clinical Endocrinology and Metabolism","first-page":"393","article-title":"The renin-angiotensin-aldosterone system in volume control","author":"Mitchell","year":"1989"},{"issue":"suppl","key":"10.1016\/j.amjmed.2003.09.034_BIB4","first-page":"S13","article-title":"Renin-angiotensin system","volume":"10","author":"Johnston","year":"1992","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1681\/ASN.V541153","article-title":"Tubular fluid concentrations and kidney contents of angiotensin I and II in anesthetized rats","volume":"5","author":"Navar","year":"1994","journal-title":"J Am Soc Nephrol"},{"issue":"suppl","key":"10.1016\/j.amjmed.2003.09.034_BIB6","first-page":"S266","article-title":"Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade","volume":"10","author":"Navar","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jama.1960.03030030014003","article-title":"Hypotensive agents and pressor substances","volume":"174","author":"Laragh","year":"1960","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB8","first-page":"24","article-title":"Regulation of sodium permeability by aldosterone","volume":"12","author":"Garty","year":"1992","journal-title":"Semin Nephrol"},{"issue":"suppl 4","key":"10.1016\/j.amjmed.2003.09.034_BIB9","first-page":"S3","article-title":"Cell biology and genetics of angiotensin in cardiovascular disease","volume":"12","author":"Dzau","year":"1994","journal-title":"J Hypertens"},{"issue":"suppl 2","key":"10.1016\/j.amjmed.2003.09.034_BIB10","first-page":"7","article-title":"The renin-angiotensin system in the vessel wall","volume":"93","author":"Muller","year":"1998","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/01.CIR.89.1.493","article-title":"Tissue angiotensin system in cardiovascular medicine","volume":"89","author":"Dzau","year":"1994","journal-title":"Circulation"},{"issue":"suppl","key":"10.1016\/j.amjmed.2003.09.034_BIB12","doi-asserted-by":"crossref","first-page":"205S","DOI":"10.1016\/S0895-7061(99)00103-X","article-title":"The renin-angiotensin-aldosterone system","volume":"12","author":"Weir","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/ki.1994.52","article-title":"The paradox of the renin-angiotensin system in chronic renal disease","volume":"45","author":"Rosenberg","year":"1994","journal-title":"Kidney Int"},{"issue":"suppl","key":"10.1016\/j.amjmed.2003.09.034_BIB14","first-page":"S239","article-title":"Pharmacologic interruption of the renin-angiotensin system and the kidney","volume":"10","author":"Hollenberg","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB15","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199606203342507","article-title":"Angiotensin receptors and their antagonists","volume":"334","author":"Wood","year":"1996","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.amjmed.2003.09.034_BIB16","first-page":"S3","article-title":"Angiotensin II receptor blockade and end-organ protection","volume":"16","author":"Unger","year":"1998","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00041552-200101000-00017","article-title":"Angiotensin II type 1-receptor gene polymorphisms in humans","volume":"10","author":"Duncan","year":"2001","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00041552-200101000-00015","article-title":"Angiotensin type 2 receptors","volume":"10","author":"Siragy","year":"2001","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1172\/JCI7886","article-title":"Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilatation","volume":"104","author":"Tsutsami","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/ndt\/15.4.448","article-title":"Angiotensin II type 2 receptors in the kidney","volume":"15","author":"Arima","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.ASN.0000043904.26730.11","article-title":"Pressure natriuresis in AT2 receptor-deficient mice with L-NAME hypertension","volume":"14","author":"Obst","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1172\/JCI114174","article-title":"Angiotensin II stimulates early proximal bicarbonate absorption in the rat by decreasing cyclic adenosine monophosphate","volume":"84","author":"Liu","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB23","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1681\/ASN.V1101146","article-title":"Angiotensin stimulates bicarbonate transport and Na+\/K+ ATPase in rat proximal straight tubules","volume":"1","author":"Garvin","year":"1991","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB24","first-page":"F143","article-title":"Effects of AII on electrolyte transport in the early and late distal tubule in rat kidney","volume":"271","author":"Wang","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB25","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/01.ASN.0000013292.78621.FD","article-title":"Angiotensin II directly stimulates EnaC activity in the cortical collecting duct via AT1 receptors","volume":"13","author":"Peti-Peterdi","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ndt\/15.suppl_6.61","article-title":"Angiotensin II as a mediator of tubulointerstitial injury","volume":"15","author":"Wolf","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00041552-200201000-00009","article-title":"Proinflammatory effects of angiotensin II and endothelin","volume":"11","author":"Luft","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB28","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/01.HYP.28.5.916","article-title":"Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase","volume":"28","author":"Tsuzuki","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB29","first-page":"622A","article-title":"Aldosterone causes TGF-\u03b2 expression","volume":"11","author":"Juknevicius","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00041552-200101000-00016","article-title":"Aldosterone in renal disease","volume":"10","author":"Hostetter","year":"2001","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB31","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1046\/j.1523-1755.2001.00020.x","article-title":"Diabetic nephropathy","volume":"60","author":"Parving","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0272-6386(96)90538-7","article-title":"Diabetic nephropathy in type II diabetes","volume":"27","author":"Ritz","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB33","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0140-6736(91)91042-S","article-title":"Chronic renal failure: pathophysiology","volume":"338","author":"Jacobson","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB35","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJM198209093071104","article-title":"Dietary protein intake and the progressive nature of kidney disease","volume":"307","author":"Brenner","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB36","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1172\/JCI112013","article-title":"Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass","volume":"76","author":"Anderson","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB37","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.2337\/diabetes.48.10.2066","article-title":"Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation","volume":"48","author":"Singh","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB38","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","article-title":"Pathophysiology of progressive nephropathies","volume":"339","author":"Remuzzi","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB39","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1681\/ASN.V125941","article-title":"Blocking angiotensin II synthesis\/activity preserves glomerular nephrin in rats with severe nephrosis","volume":"12","author":"Benigni","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB40","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s001250100546","article-title":"Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension","volume":"44","author":"Bonnet","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/ndt\/14.2.304","article-title":"Nephrotoxicity of increased glomerular protein traffic","volume":"14","author":"Abbate","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB42","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1046\/j.1523-1755.1999.00614.x","article-title":"Effect of candesartan cilexetil in rats with chronic renal failure","volume":"56","author":"Noda","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1291\/hypres.22.303","article-title":"Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis","volume":"22","author":"Nakaya","year":"1999","journal-title":"Hypertens Res"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB44","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2337\/diacare.46.10.1612","article-title":"Role of angiotensin II and bradykinin in experimental diabetic nephropathy","volume":"46","author":"Allen","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000020502","article-title":"Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism","volume":"6","author":"Remuzzi","year":"1998","journal-title":"Exp Nephrol"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.HYP.0000049881.25304.73","article-title":"Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent","volume":"41","author":"Griffin","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB47","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB48","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB49","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin converting enzyme inhibitors and progression on nondiabetic renal disease","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB51","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB52","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB53","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB54","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB55","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1681\/ASN.V1341100","article-title":"ACE inhibitors versus AT1 receptor antagonists in patients with chronic renal disease","volume":"13","author":"Hilgers","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB56","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB57","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction in patients with type 2 diabetes mellitus","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB58","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/diacare.25.1.95","article-title":"Dual blockade of renin-angiotensin system in diabetic nephropathy","volume":"25","author":"Rossing","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/ajkd.2001.25176","article-title":"Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy","volume":"38","author":"Russo","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004872-200018010-00013","article-title":"Safety of combination of valsartan and benazepril in patients with chronic kidney disease. European Group for the Investigation of Valsartan in Chronic Renal Disease","volume":"18","author":"Ruilope","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB62","doi-asserted-by":"crossref","unstructured":"Luno J, Barrio V, Goicoechea, et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int. 2002;62(suppl):S47-S52","DOI":"10.1046\/j.1523-1755.62.s82.10.x"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE)","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB64","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1046\/j.1523-1755.2001.00745.x","article-title":"Add on angiotensin receptor blockade with maximized ACE inhibition","volume":"59","author":"Agarwal","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB65","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","article-title":"Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity","volume":"63","author":"Feria","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB67","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB68","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB69","doi-asserted-by":"crossref","first-page":"249A","DOI":"10.1016\/S0735-1097(02)81115-9","article-title":"Eplerenone reduces proteinuria in type 2 diabetes mellitus","volume":"39","author":"Epstein","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2003.09.034_BIB70","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","article-title":"Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone","volume":"110","author":"Schepkens","year":"2001","journal-title":"Am J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934303006879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934303006879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:27:44Z","timestamp":1757579264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934303006879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0002934303006879"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2003.09.034","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2003.09.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Excerpta Medica Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}